Bringing ayahuasca to the clinical research laboratory

Journal of Psychoactive Drugs

Volumn 37, Issue 2, 2005, Pages 219-230

  Riba, Jordi ^a,b   Barbanoj, Manel J ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Ayahuasca; Clinical pharmacology; DMT; Human; Psychedelics; Review

Indexed keywords

AYAHUASCA; HARMALINE; HARMINE; N,N DIMETHYLTRYPTAMINE; PSYCHEDELIC AGENT; TETRAHYDROHARMINE; UNCLASSIFIED DRUG;

ANXIETY; BEVERAGE; CARDIOVASCULAR EFFECT; CLINICAL LABORATORY; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; COLD SENSATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; GASTROINTESTINAL DISEASE; HEAT SENSATION; HUMAN; HYPERTENSION; NAUSEA; QUESTIONNAIRE; REVIEW; SIDE EFFECT; TRADITIONAL MEDICINE;

EID: 23344444861     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2005.10399804     Document Type: Article

References (35)

1. Anderer, P.; Semlitsch, H.V.; Saletu, B. & Barbanoj, M.J. 1992. Artifact processing in topographic mapping of electroencephalografic activity in neuropsychopharmacology. Psychiatry Research Neuroimaging 45:79-93.
2. Anderer, P.; Saletu, B.; Kinsperger, K. & Semlitsch, H. 1987. Topographic brain mapping of EEG in neuropsychopharmacology - Part I. Methodological aspects. Methods and Findings in Experimental and Clinical Pharmacology 9:371-84.
3. Buckholtz, N.S. & Boggan, W.O. 1977a. Monoamine oxidase inhibition in brain and liver produced by P-carbolines: Structure-activity relationships and substrate specificity. Biochemical Pharmacology 26: 1991-96.
4. Buckholtz, N.S. & Boggan, W.O. 1977b. Inhibition by P-carbolines of monoamine uptake into a synaptosomal preparation: structure-activity relationships. Life Science 20: 2093-99.
5. Callaway, J.C.; McKenna, D.J.; Grob, C.S.; Brito, G.S.; Raymon, L.P.; Poland, R.E.; Andrade, E.N.; Andrade, E.O. & Mash, D.C. 1999. Pharmacokinetics of hoasca alkaloids in healthy humans. Journal of Ethnopharmacology 65: 243-56.
6. Callaway, J.C.; Raymon, L.P.; Hearn, W.L.; McKenna, D.J.; Grob, C.S. & Brito, G.S. 1996. Quantitation of N, N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. Journal of Analytical Toxicology 20: 492-97.
7. Dittrich, A. 1998. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31 (Suppl 2): 80-4.
8. Ferber, G.; Abt, K.; Fichte, K. & Luthringer, R. 1999.IPEG guideline on statistical design and analysis for pharmacodynamic trials. International Pharmaco-EEG group. Neuropsychobiology 39: 92-100.
9. Fish, M.S.; Johnson, N.M.; Lawrence, E.P. & Horning, EC. 1955. Oxidative N-dealkylation. Biochemical and Biophysical Acta 18: 564-65.
10. I50]-PET and LORETA during cognitive and pharmacological activation. Human Brain Mapping 22: 83-96.
11. Gouzoulis-Mayfrank, E.; Thelen, B.; Habermeyer, E.; Kunert, H.J.; Kovar, K.A.; Lindenblatt, H.; Hermle, L.; Spitzer, M. & Sass, H. 1999. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Psychopharmacology 142: 41-50.
12. Itil, T. & Fink, M. 1966. Klinische Untersuchungen und quantitative EEG-Daten bei experimentellen Psychosen. Arzneimittelforschung 16: 237-39.
13. Koulu, M.; Scheinin, M.; Kaarttinen, A.; Kallio, J.; Pyykko, K.; Vuorinen, J. & Zimmer, R.H. 1989. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. British Journal of Clinical Pharmacology 27:243-55.
14. Lee, D.Y.; Lee, K.U.; Kwon, J.S.; Jang, I.J.; Cho, M.J.; Shin, S.G. & Woo, J.I. 1999. Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers. Psychopharmacology 144: 272-78.
15. Martin, W.R.; Sloan, J.W.; Sapira, J.D. & Jasinski, D.R. 1971. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology and Therapeutics 12:245-258.
16. Nunez, P.L. & Silberstein, R.B. 2000. On the relationship of synaptic activity to macroscopic measurements: does co-registration ofEEG with fMRI make sense? Brain Topography 13: 79-96
17. Ott, J. 1999. Pharmahuasca: Human pharmacology of oral DMT plus harmine. Journal of Psychoactive Drugs 31: 171-77.
18. Ott, J. 1993. Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History. Kennewick, Washington: Natural Products Co.
19. Pascual-Marqui, R.D.; Michel, C.M. & Lehmann, D. 1994. Low resolution electromagnetic tomography: A new method for localizing electrical activity in the brain. International Journal of Psychophysiology 18: 49-65.
20. Pletscher, A. 1966. Monoamine oxidase inhibitors. Pharmacological Reviews 18: 121-29.
21. Riba, J. 2003. Human pharmacology of ayahuasca. Doctoral dissertation, Barcelona, Universitat Autonoma de Barcelona.
22. Riba, J.; Anderer, P.; Jane, F.; Saletu, B. & Barbano, M.J. 2004. Effects of the South American psychoactive beverage Ayahuasca on regional brain electrical activity in humans: A functional neuroimaging study using low resolution electromagnetic tomography (LORETA) Neuropsychobiology 50: 89-101.
23. Riba, J.; Valle, M.; Urbano, G.; Yritia, M.; Morte, A. & Barbanoj, M.J. 2003. Human pharmacology of Ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics 306: 73-83.
24. Riba, J.; Anderer, P.; Morte, A.; Urbano, G.; Jane, F.; Saletu, B. & Barbanoj, M.J. 2002a. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage Ayahuasca in healthy volunteers. British Journal of Clinical Pharmacology 53:613-628.
25. Riba, J.; Rodffguez-Fomells, A. & Barbanoj, M.J. 2002b. Effects of Ayahuasca on sensory and sensorimotor gating in humans, as measured by P5O suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology 165: 18-28.
26. Riba, J.; Rodffguez-Fomells, A., Strassman, R.J. & Barbanoj, M.J. 2001a. Psychometric assessment of the Hallucinogen Rating Scale. Drug and Alcohol Dependence 62: 215-23.
27. Riba, J.; Rodffguez-Fomells, A.; Urbano, G.; Morte, A.; Antonijoan, R.; Montero, M.; Callaway, J.C. & Barbanoj, M.J. 2001b. Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology 154: 85-95.
28. Saletu, B.; Barbanoj, M.J.; Anderer, P.; Sieghart, W. & Griinberger, J. 1993. Clinical-pharmacological study with two isomers (d-, 1-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: Blood levels, EEG mapping and safety evaluation. Methods and Findings in Experimetal and Clinical Pharmacology 15: 291-312.
29. Spruce, R. 1908. Notes of a Botanist on the Amazon and Andes, Vol 2. London: Macmillan.
30. Strassman, R.J. & Qualls, C.R. 1994. Dose-response study of N, N-dimethyltryptamine in humans, I. Neuroendocrine, autonomic and cardiovascular effects. Archives of General Psychiatry 51: 85-97.
31. Strassman, R.J.; Qualls, C.R.; Uhlenhuth, E.H. & Kellner, R. 1994. Dose-response study ofN, N-dimethyltryptamine in humans, II. Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry 51: 98-108.
32. Szeira, S. 1956. Dimethyltryptamine: Its metabolism in man; the relation of its psychotic effect to the serotonin metabolism. Experientia 12: 441-42.
33. Vollenweider, F.X.; Leenders, K.L.; Scharfetter, C.; Maguire, P.; Stadelmann, O. & Angst, J. 1997. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357-72.
34. Yritia, M.; Riba, J.; Ortuno, J.; Ramirez, A.; Castillo, A.; Alfaro, Y.; de Ia Torre, R. & Barbanoj, M.J. 2002. Determination of N, N-dimethyltryptamine and b-carboline alkaloids in human plasma following oral administration of Ayahuasca. Journal of Chromatography: Biomedical Applications 779:271-281.
35. Yu, A.; Idle, J.R.; Krausz, K.W.; Kupfer, A. & Gonzalez, F.J. 2003. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic (3-carboline alkaloids hannaline and harmine. Journal of Pharmacology and Experimental Therapeutic 305: 315-22.